Leerink analyst Geoffrey Porges lowered his price target for Alexion to $208 from $217 after the company disclosed the sBLA for Soliris in myasthenia gravis was accepted by the FDA with a PDUFA date of October 23, 2017, and clarified that the timing for its neuromyelitis optica Phase 3 results will be 2018, not 2017. The analyst noted that both updates delay the launch and ramp of revenues for these indications in his model, as he previously assumed myasthenia gravis launched in mid-2017 and neuromyelitis optica launched in 2018. He reiterates an Outperform rating on the shares.